Kazuhiko Mori

Dr. Kazuhiko Mori

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2000 in Journal of Pharmacy and Pharmacology
Verified
Journal Article
Open access
PDF file
KMKazuhiko Mori
Kazuhiko Mori
CMChikako Maru
Chikako Maru
KTKiyoshi Takasuna
Kiyoshi Takasuna
Characterization of histamine release induced by fluoroquinolone antibacterial agents, levofloxacin and ciprofloxacin, was investigated in-vivo and in-vitro. Intravenous injection of levofloxacin and ciprofloxacin at 1–10 mg kg−1 produced dose-related elevations in plasma histamine level in anaesthetized dogs. In contrast, levofloxacin was devoid of plasma histamine increment in anaesthetized rats at 100 mg kg−1, whereas ciprofloxacin at the same dose caused endogenous histamine release. Levofloxacin and ciprofloxacin induced non-cytotoxic secretion of histamine from all mast cells tested in a concentration-dependent manner, whereas rat skin and peritoneal mast cells were thirty- to one-hundred-times less sensitive to the effect of fluoroquinolones as compared with the canine skin mast cells. These results suggest that the functional heterogeneity of mast cells from different species in histamine releasing activity of fluoroquinolones may exist, and that mast cells from the dog appear to be particularly sensitive to the effect of the fluoroquinolones.

4 October 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
NANoriaki Arakawa
Noriaki Arakawa
AUAtsuhito Ushiki
Atsuhito Ushiki
MAMitsuhiro Abe
Mitsuhiro Abe
SMShinichiro Matsuyama
Shinichiro Matsuyama
YSYoshinobu Saito
Yoshinobu Saito
MHMasayuki Hanaoka
Masayuki Hanaoka
Among the various histopathological patterns of drug-induced interstitial lung disease (DILD), diffuse alveolar damage (DAD) is associated with poor prognosis. However, there is no reliable biomarker for its accurate diagnosis. Here, we show stratifin/14-3-3σ (SFN) as a biomarker candidate found in a proteomic analysis. The study includes two independent cohorts (including totally 26 patients with DAD) and controls (total 432 samples). SFN is specifically elevated in DILD patients with DAD, and is superior to the known biomarkers, KL-6 and SP-D, in discrimination of DILD patients with DAD from patients with other DILD patterns or other lung diseases. SFN is also increased in serum from patients with idiopathic DAD, and in lung tissues and bronchoalveolar lavage fluid of patients with DAD. In vitro analysis using cultured lung epithelial cells suggests that extracellular release of SFN occurs via p53-dependent apoptosis. We conclude that serum SFN is a promising biomarker for DAD diagnosis.

30 September 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
EHEri Hamamura-Yasuno
Eri Hamamura-Yasuno
TITakuma Iguchi
Takuma Iguchi
KKKazuyoshi Kumagai
Kazuyoshi Kumagai
YTYoshimi Tsuchiya
Yoshimi Tsuchiya
KMKazuhiko Mori
Kazuhiko Mori
MAS-related G protein coupled receptor-X2 (MRGPRX2), expressed in human mast cells, is associated with drug-induced pseudo-allergic reactions. Dogs are highly susceptible to drug-induced anaphylactoid reactions caused by various drugs; however, the distribution and physiological function of canine MRGPR family genes, including MRGPRX2, remain largely unknown. In the present study, we clarified the distribution of dog MRGPR family genes by real-time quantitative PCR and in situ hybridisation. We also investigated the stimulatory effects of various histamine-releasing agents, including fluoroquinolones, on HEK293 cells transiently transfected with dog MRGPR family genes to identify their physiological function. Dog MRGPRX2 and MRGPRG were distributed in a limited number of tissues, including the skin (from the eyelid, abdomen, and cheek), whereas MRGPRD and MRGPRF were extensively expressed in almost all tissues examined. Histochemical and in situ hybridisation analyses revealed that MRGPRX2 was expressed in dog connective tissue-type mast cells in the skin. Intracellular Ca2+ mobilisation assay revealed that HEK293 cells, expressing dog MRGPRX2 or human MRGPRX2, but not dog MRGPRD, MRGPRF, and MRGPRG, responded to histamine-releasing agents. Our results suggest that dog MRGPRX2 is the functional orthologue of human MRGPRX2 and plays an essential role in drug-induced anaphylactoid reactions in dogs.

1 October 2018 in Toxicology Letters
Verified
Journal Article
Closed access
WSWataru Saitoh
Wataru Saitoh
STSanae Takada
Sanae Takada
JHJun Hirao
Jun Hirao
MSMakoto Shirai
Makoto Shirai
TITakuma Iguchi
Takuma Iguchi
KMKazuhiko Mori
Kazuhiko Mori

22 July 2008 in Toxicology and Applied Pharmacology
Verified
Journal Article
Closed access
TNTakayoshi Nishiya
Takayoshi Nishiya
KMKazuhiko Mori
Kazuhiko Mori
CHChiharu Hattori
Chiharu Hattori
KKKiyonori Kai
Kiyonori Kai
HKHiroko Kataoka
Hiroko Kataoka
SMSunao Manabe
Sunao Manabe

31 August 2020 in Metabolites
Verified
Journal Article
Open access
PDF file
KSKosuke Saito
Kosuke Saito
Tatehiro KagawaTatehiro Kagawa
Tatehiro Kagawa
KTKeiji Tsuji
Keiji Tsuji
YKYuji Kumagai
Yuji Kumagai
KSKen Sato
Ken Sato
HTHajime Takikawa
Hajime Takikawa
Drug-induced liver injury (DILI) is a major adverse event caused by drug treatment, which can be categorized into three types: hepatocellular, mixed, and cholestatic. Although nearly every class of drugs can cause DILI, an overall understanding of lipid profiles in DILI patients is lacking. We used lipidomics to analyze the plasma lipid profiles of patients to understand their hepatic pathophysiology and identify DILI biomarkers. We identified 463 lipids and compared their levels between the acute and recovery phases of the three types of DILI patients. Mixed and cholestatic types demonstrated specific plasma lipid alterations between the phases, but the hepatocellular type did not. Moreover, as specific indicators of mixed-type DILI, levels of several ceramides increased in the acute phase, while those of arachidonic acid-containing ether-linked phosphoglycerolipids decreased. In contrast, as specific indicators of cholestatic-type DILI, levels of palmitic acid-containing saturated or monounsaturated phosphatidylcholines increased in the acute phase, while those of arachidonic acid- or docosahexaenoic acid-containing ether-linked phosphoglycerolipids and phosphatidylinositols decreased. We also identified lipids with a relatively high capacity to discriminate the acute phase from the recovery phase and healthy subjects. These findings may help with understanding the pathophysiology of different DILI types and identify candidate biomarkers.